Investigational drug · Phase 3
M-M-R II vaccine
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Pneumococcal Immunization.
Phase 3Last checked: Nov 20, 2026Latest source record: Apr 22, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
3
3 still active
All registered trials
136
Any phase or sponsor naming "M-M-R II vaccine"
First trial start
2024
Dec 18, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "M-M-R II vaccine", any sponsor or status.
Conditions studied
As listed on its trial records.
- Pneumococcal Immunization
Largest trials
Live from ClinicalTrials.gov: studies naming "M-M-R II vaccine" as an intervention, largest first.
- Safety Observation of Enterovirus 71 Inactivated Vaccine (Vero Cell) Combined Immunization in ShanghaiStatus unknown
Sinovac Biotech Co., LtdIndustry
NCT05166044 · 12,500 participants (planned) · Start Jan 4, 2022 · Primary completion Jun 4, 2022
Drug: EV71 Inactivated Vaccine · For: Hand, Foot and Mouth Disease
Sites: Baoshan, China; Jing’an, China; Minhang, China · 6 sites in all
- MMR at 6 Months TrialPivotal-lookingCompleted
Copenhagen University Hospital, RigshospitaletAcademic, hospital or other
NCT03780179 · 6,540 participants · Start Apr 15, 2019 · Primary completion Jan 7, 2022
Drug: MMRvaxpro; Placebo · For: Meales-mumps-rubella Vaccine
Sites: Copenhagen, Denmark; Herlev, Denmark
- MMR and MMRV Vaccines: Effect of Age at First Dose on Safety and Immunogenicity of the Measles Component.Status unknown
CHU de Quebec-Universite LavalAcademic, hospital or other
NCT02712203 · 5,808 participants · Start Jul 2004 · Primary completion Jul 2010
Drug: MMR vaccine / MMRV vaccine · For: Measles
- Evaluate Vaccine Against Chickenpox and a Combined Vaccine Against 4 Viral Childhood Diseases: Measles, Mumps, Rubella and ChickenpoxPivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT00226499 · 5,803 participants · Start Sep 1, 2005 · Primary completion Oct 12, 2006
Drug: Priorix-tetra™; Priorix™ and 1 more · For: Varicella; Chickenpox Vaccines
Sites: Brno, Czechia; Chomutov, Czechia; Děčín, Czechia · 104 sites in all
- Consistency Study of GlaxoSmithKline (GSK) Biologicals' MMR Vaccine (209762) (Priorix) Comparing Immunogenicity and Safety to Merck & Co., Inc.'s MMR Vaccine (M-M-R II), in Children 12 to 15 Months of AgePivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT01702428 · 5,016 participants · Start Nov 9, 2012 · Primary completion Nov 25, 2014
Drug: Priorix; M-M-R II and 3 more · For: Rubella; Measles; Mumps
Sites: Dothan, Alabama; Phoenix, Arizona; Fayetteville, Arkansas · 90 sites in all
- Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Children in Their Second Year of LifePivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT01681992 · 4,538 participants · Start Oct 10, 2012 · Primary completion Feb 3, 2015
Drug: Priorix; M-M-R II and 3 more · For: Measles; Mumps; Rubella and 1 more
Sites: Birmingham, Alabama; Phoenix, Arizona; Jonesboro, Arkansas · 81 sites in all
- Bexsero™and Routine Infant Vaccines: Effect of Coadministration on the Safety of ImmunizationCompleted
CHU de Quebec-Universite LavalAcademic, hospital or other
NCT02712177 · 4,535 participants · Start Aug 2008 · Primary completion Aug 2010
Drug: 4CMenb; diphtheria,tetanus,pertussis+polio+Hepatitis B+HiB and 2 more · For: Meningococcal Infections
- Safety and Immunogenicity Study of Hib-MenCY-TT Vaccine Compared to Licensed Hib Conjugate VaccinePivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT00289783 · 4,441 participants · Start Feb 22, 2006 · Primary completion Aug 27, 2007
Drug: GSK Biologicals' Haemophilus influenzae type b and Neisseria meningitidis 792014 vaccine; ActHIB and 5 more · For: Haemophilus Influenzae Type b; Neisseria Meningitidis
Sites: Birmingham, Alabama; Phoenix, Arizona; Bryant, Arkansas · 93 sites in all
- Immune Response and Safety Comparison of 3 Lots of GSK Biologicals' DTaP-IPV Candidate Vaccine to DTaP + IPV VaccinesPivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT00148941 · 4,209 participants · Start Jan 6, 2005 · Primary completion Nov 1, 2006
Drug: SB213503 lot 1; SB213503 lot 2 and 4 more · For: Tetanus; Acellular Pertussis; Diphtheria
Sites: Little Rock, Arkansas; Antioch, California; Daly City, California · 24 sites in all
- Safety of Hib-MenCY-TT Vaccine Versus Licensed Hib Conjugate Vaccine, Given at 12 to 15 Months of Age.Pivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT00345683 · 4,021 participants · Start Jul 2007 · Primary completion Sep 2008
Drug: GSK Biologicals' Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine combined (792014); PedvaxHIB and 3 more · For: Haemophilus Influenzae Type b; Neisseria Meningitidis
Sites: Birmingham, Alabama; Benton, Arkansas; Jonesboro, Arkansas · 57 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Securing long-term immunity: The possible necessity of supplementary measles vaccination.
Kalayci F, Yigit M, Gulhan B, et al. · BMC Infect Dis 2024
- Associations of adaptive immune cell subsets with measles, mumps, and Rubella-Specific immune response outcomes.
Wang L, Haralambieva IH, Ovsyannikova IG, et al. · Heliyon 2023
- Physical interventions and injection techniques for reducing injection pain during routine childhood immunizations: systematic review of randomized controlled trials and quasi-randomized controlled trials.
Taddio A, Ilersich AL, Ipp M, et al. · Clin Ther 2009
- Neutralization activity and persistence of antibodies induced in response to vaccination with a novel mumps strain, RIT 4385.
Usonis V, Bakasenas V, Denis M · Infection 2001
- Postmarketing evaluation of the safety and effectiveness of varicella vaccine.
Black S, Shinefield H, Ray P, et al. · Pediatr Infect Dis J 1999
- Comparative study of reactogenicity and immunogenicity of new and established measles, mumps and rubella vaccines in healthy children.
Usonis V, Bakasenas V, Chitour K, et al. · Infection 1998
Also in development for Pneumococcal Immunization
- PCV21 vaccinePhase 35 trials
Sanofi · Pneumococcal Immunization, Healthy Volunteers
- DTap-HepB-IPV-Hib vaccineHexyon, Infanrix hexaPhase 34 trials
Sanofi · Healthy Volunteers, Meningococcal Immunization, Pneumococcal Immunization
- HexaximHexaxim Vaccine, DTaP-IPV-Hib-HepB vaccinePhase 32 trials
Sanofi · Pneumococcal Immunization, Meningococcal Immunisation, Healthy Volunteers
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Sanofi.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.